Market Overview

William Blair Analyst: DaVita Set to Gain from Medicare Advantage Reimbursement Increase

Related DVA
Earnings Scheduled For May 3, 2018
DaVita Earnings Preview

William Blair analyst Ben Andrew released comments Tuesday morning expressing confidence in DaVita Healthcare (NYSE: DVA), following the victory by health insurers to get the reimbursement for Medicare Advantage increased by 3.3 percent on Monday.

The decision against a reduction in Medicare reimbursements was cited as a reduction in near-term headwinds, while also improving the company's position in the long-term. DaVita was highlighted as one of the "best positioned" companies to benefit from this ruling, and is maintained at an Outperform rating.

Shares of DaVita Healthcare traded up 5.51 percent to $126.52.

Latest Ratings for DVA

Jun 2018William BlairAssumesOutperform
Jan 2018Bank of AmericaUpgradesNeutralBuy
Dec 2017CitigroupUpgradesNeutralBuy

View More Analyst Ratings for DVA
View the Latest Analyst Ratings

Posted-In: William BlairAnalyst Color News Legal Analyst Ratings Movers


Related Articles (DVA)

View Comments and Join the Discussion!